BioCentury | Feb 2, 2021
Product Development

Feb. 2 Quick Takes: Immunovant tumbles as it pauses trial; plus BMS, Legend-J&J, Arcutis, Prothena, VBI, Travere, Concert and Adamas

...prespecified interim analysis of the pivotal Phase III DUPLEX study. Shares of the company, formerly Retrophin Inc....
BioCentury | Oct 24, 2020
Product Development

Oct. 23 Quick Takes: Ultragenyx, Solid in DMD gene therapy deal; plus IAVI-Merck KGaA-Serum Institute, BiondVax, Retrophin-Orphan Technologies, and more

...and secondary endpoints in a Phase III trial.Retrophin...
...Initiative (IAVI) Merck KGaA Serum Institute of India Pvt. Ltd. Retrophin Inc. The...
BioCentury | Jun 12, 2020
Finance

May’s momentum continues as Catalent, eight others price follow-ons

...proposed after-hours to raise $100 million. On Thursday, CareDx’s stock fell $3.29 (10%) to $30.22. Retrophin Inc....
...million Wednesday. Elizabeth S. Eaton, Staff Writer Moderna Inc. Guardant Health Inc. Allogene Therapeutics Inc. Catalent Inc. ChemoCentryx Inc. Fate Therapeutics Inc. CareDx Inc. Retrophin Inc. Replimune...
BioCentury | Jan 11, 2020
Company News

Management Tracks: Wave CFO departs; plus Polaris, Turning Point, ADC, Relmada, Aravive, Affimed, Impel, Candel and more

...COO. Poole was COO at LogicBio Therapeutics Inc. (NASDAQ:LOGC) and serves on the boards of Retrophin Inc....
BioCentury | Oct 4, 2019
Company News

Management tracks: J&J hires Bayer’s Swanson; plus Torque, Dynavax, Pact, Deciphera, NextCure, Retrophin, Verve, Jnana and more

...COO. Mayer has been with the immunotherapy company since its 2015 founding. Rare disease play Retrophin Inc....
...Lori Reilly, who became COO on Sept. 17. BioCentury Staff Torque Therapeutics Inc. Pact Pharma Inc. Deciphera Pharmaceuticals Inc. NextCure Inc. Retrophin Inc. Vor...
BioCentury | Aug 22, 2019
Clinical News

After neurodegeneration miss, Retrophin looks to rebound with renal program

...With plans to discontinue fosmetpantotenate after its Phase III miss, Retrophin President and CEO Eric Dube...
...Retrophin Inc. (NASDAQ:RTRX) down $3.84 (22%) to $13.56 Thursday, well below its 52-week high of $33. Retrophin...
...nephropathy. The company expects top-line data from DUPLEX and PROTECT in 1H21 and 1H22, respectively. Retrophin...
BioCentury | Aug 16, 2019
Emerging Company Profile

Grace: seeking cures in pathological roots

...for NGLY1 deficiency, companies including Retrophin Inc. and Glycomine Inc. have preclinical programs for the disorder. Retrophin...
...Menlo Park, Calif. Reata Pharmaceuticals Inc. (NASDAQ:RETA), Irving, Texas Regeneron Pharmaceutical Inc. (NASDAQ:REGN), Tarrytown, N.Y. Retrophin Inc....
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...events (MACE) in patients with Type II diabetes and high HDL Phase III data YE19 Retrophin Inc....
BioCentury | Jun 19, 2019
Company News

June 19 Company Quick Takes: Catalent takes over manufacturing site from BMS; plus Lynparza, Myriad, Amgen and more

...a biomedical business this year in North America. Retrophin partners with NCATS on Alagille treatment Retrophin Inc....
...MK-7339) Amgen Inc. AstraZeneca plc Bristol-Myers Squibb Co. Catalent Inc. Merck & Co. Inc. Myriad Genetics Inc. National Center for Advancing Translational Sciences Retrophin Inc. University...
BioCentury | Apr 22, 2019
Company News

Management tracks: MeiraGTx, Retrophin, Aduro

...gene therapy company. MeiraGTx said COO Richard Giroux will take on the role of CFO. Retrophin Inc....
...protein 173; TNFSF13 (APRIL) - Tumor necrosis factor ligand superfamily member 13 BioCentury Staff Aduro Biotech Epic Sciences MeiraGTx Neurelis Prime Therapeutics Retrophin Sofinnova...
Items per page:
1 - 10 of 103
BioCentury | Feb 2, 2021
Product Development

Feb. 2 Quick Takes: Immunovant tumbles as it pauses trial; plus BMS, Legend-J&J, Arcutis, Prothena, VBI, Travere, Concert and Adamas

...prespecified interim analysis of the pivotal Phase III DUPLEX study. Shares of the company, formerly Retrophin Inc....
BioCentury | Oct 24, 2020
Product Development

Oct. 23 Quick Takes: Ultragenyx, Solid in DMD gene therapy deal; plus IAVI-Merck KGaA-Serum Institute, BiondVax, Retrophin-Orphan Technologies, and more

...and secondary endpoints in a Phase III trial.Retrophin...
...Initiative (IAVI) Merck KGaA Serum Institute of India Pvt. Ltd. Retrophin Inc. The...
BioCentury | Jun 12, 2020
Finance

May’s momentum continues as Catalent, eight others price follow-ons

...proposed after-hours to raise $100 million. On Thursday, CareDx’s stock fell $3.29 (10%) to $30.22. Retrophin Inc....
...million Wednesday. Elizabeth S. Eaton, Staff Writer Moderna Inc. Guardant Health Inc. Allogene Therapeutics Inc. Catalent Inc. ChemoCentryx Inc. Fate Therapeutics Inc. CareDx Inc. Retrophin Inc. Replimune...
BioCentury | Jan 11, 2020
Company News

Management Tracks: Wave CFO departs; plus Polaris, Turning Point, ADC, Relmada, Aravive, Affimed, Impel, Candel and more

...COO. Poole was COO at LogicBio Therapeutics Inc. (NASDAQ:LOGC) and serves on the boards of Retrophin Inc....
BioCentury | Oct 4, 2019
Company News

Management tracks: J&J hires Bayer’s Swanson; plus Torque, Dynavax, Pact, Deciphera, NextCure, Retrophin, Verve, Jnana and more

...COO. Mayer has been with the immunotherapy company since its 2015 founding. Rare disease play Retrophin Inc....
...Lori Reilly, who became COO on Sept. 17. BioCentury Staff Torque Therapeutics Inc. Pact Pharma Inc. Deciphera Pharmaceuticals Inc. NextCure Inc. Retrophin Inc. Vor...
BioCentury | Aug 22, 2019
Clinical News

After neurodegeneration miss, Retrophin looks to rebound with renal program

...With plans to discontinue fosmetpantotenate after its Phase III miss, Retrophin President and CEO Eric Dube...
...Retrophin Inc. (NASDAQ:RTRX) down $3.84 (22%) to $13.56 Thursday, well below its 52-week high of $33. Retrophin...
...nephropathy. The company expects top-line data from DUPLEX and PROTECT in 1H21 and 1H22, respectively. Retrophin...
BioCentury | Aug 16, 2019
Emerging Company Profile

Grace: seeking cures in pathological roots

...for NGLY1 deficiency, companies including Retrophin Inc. and Glycomine Inc. have preclinical programs for the disorder. Retrophin...
...Menlo Park, Calif. Reata Pharmaceuticals Inc. (NASDAQ:RETA), Irving, Texas Regeneron Pharmaceutical Inc. (NASDAQ:REGN), Tarrytown, N.Y. Retrophin Inc....
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...events (MACE) in patients with Type II diabetes and high HDL Phase III data YE19 Retrophin Inc....
BioCentury | Jun 19, 2019
Company News

June 19 Company Quick Takes: Catalent takes over manufacturing site from BMS; plus Lynparza, Myriad, Amgen and more

...a biomedical business this year in North America. Retrophin partners with NCATS on Alagille treatment Retrophin Inc....
...MK-7339) Amgen Inc. AstraZeneca plc Bristol-Myers Squibb Co. Catalent Inc. Merck & Co. Inc. Myriad Genetics Inc. National Center for Advancing Translational Sciences Retrophin Inc. University...
BioCentury | Apr 22, 2019
Company News

Management tracks: MeiraGTx, Retrophin, Aduro

...gene therapy company. MeiraGTx said COO Richard Giroux will take on the role of CFO. Retrophin Inc....
...protein 173; TNFSF13 (APRIL) - Tumor necrosis factor ligand superfamily member 13 BioCentury Staff Aduro Biotech Epic Sciences MeiraGTx Neurelis Prime Therapeutics Retrophin Sofinnova...
Items per page:
1 - 10 of 103